Literature DB >> 11156241

Interstitial collagenases as markers of tumor progression.

C E Brinckerhoff1, J L Rutter, U Benbow.   

Abstract

Degradation of the extracellular matrix is the sine qua non of tumor invasion and metastasis. Most of this degradation is mediated by matrix metalloproteinases (MMPs), a family of enzymes that, collectively, degrades the extracellular matrix. Although the basement membrane-degrading enzymes, MMP-2 and MMP-9, have been given considerable attention for their roles in invasion and metastasis, the interstitial collagenases, a subfamily of MMPs that cleaves the stromal collagens types I and III, have received relatively little recognition for their part in these processes. This subfamily is comprised of collagenase 1 (MMP-1), collagenase 3 (MMP-13), and the MT-MMPs, membrane-bound MMPs, and numerous reports over the last several years document the expression of these MMPs in a wide variety of advancing tumors. Of particular interest is a single nucleotide polymorphism in the MMP-1 promoter that increases the transcription of this gene and that is associated with melanoma and with ovarian and endometrial cancers. The collagenases can mediate tumor invasion through several mechanisms, which include constitutive production of enzyme by the tumor cells, induction of collagenase production in the neighboring stromal cells, and interactions between tumor/ stromal cells to induce collagenase production by one or both cell types. Thus, evidence indicates that elevated expression of the interstitial collagenases is associated with a poor prognosis in a variety of cancers, and therefore, these MMPs can serve as a marker of tumor progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156241

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  111 in total

1.  MMP2 expression is a prognostic marker for primary melanoma patients.

Authors:  Anand Rotte; Magdalena Martinka; Gang Li
Journal:  Cell Oncol (Dordr)       Date:  2012-06-06       Impact factor: 6.730

Review 2.  Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.

Authors:  Jie Wang; Ze Lu; Yue Gao; M Guillaume Wientjes; Jessie L-S Au
Journal:  Nanomedicine (Lond)       Date:  2011-11       Impact factor: 5.307

Review 3.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

Review 4.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

5.  What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?

Authors:  Ferdinando Mannello
Journal:  BMC Med       Date:  2011-08-11       Impact factor: 8.775

6.  ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3.

Authors:  Sonali Ghosh; Moitri Basu; Sib Sankar Roy
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

7.  Relationship between matrix metalloproteinase 2 and lung cancer progression.

Authors:  Chun-Bao Guo; Shan Wang; Chun Deng; Dian-Liang Zhang; Fu-Ling Wang; Xian-Qing Jin
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

8.  Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Rian Disci; Sidika Kurul; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

9.  ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.

Authors:  Xin Lu; Qiongqing Wang; Guohong Hu; Catherine Van Poznak; Martin Fleisher; Michael Reiss; Joan Massagué; Yibin Kang
Journal:  Genes Dev       Date:  2009-07-16       Impact factor: 11.361

Review 10.  Tumour endoproteases: the cutting edge of cancer drug delivery?

Authors:  J M Atkinson; C S Siller; J H Gill
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.